Research & Development

Incyte and Syndax to jointly develop and commercialise axatilimab

Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases.

AstraZeneca partners with VaxEquity on self-amplifying RNA therapeutics

AstraZeneca has entered a strategic, long-term research collaboration with biopharmaceutical firm VaxEquity to discover, develop and commercialise self-amplifying RNA (saRNA) therapeutics platform.

Tonix and Columbia University to develop tailored Covid-19 vaccines

Tonix Pharmaceuticals has expanded its research partnership with Columbia University in the US for the development of tailored Covid-19 vaccines and treatments with precision medicine.

AbCellera, Everest Medicines partner to discover new antibody therapies

Canadian biotechnology firm AbCellera has signed a collaboration and licence agreement with Everest Medicines to advance new antibody therapies.

Boehringer acquires Abexxa Biologics to develop novel cancer therapies

German pharmaceutical firm Boehringer Ingelheim has acquired Abexxa Biologics to expand its research efforts in cancer immunology and novel immunotherapeutic approaches.

Grifols to acquire Tiancheng Pharmaceutical for $1.3bn

Spanish healthcare firm Grifols has agreed to acquire 100% stake in Tiancheng (Germany) Pharmaceutical from Tiancheng International Investment for $1.289bn (€1.1bn).

Sanofi completes purchase of mRNA therapies firm Translate Bio

Sanofi has completed the acquisition of messenger RNA (mRNA) therapies firm Translate Bio to expedite the use mRNA technology for the development of treatments and vaccines.

EnGeneIC begins Phase I trial of nanocellular vaccine for Covid-19

EnGeneIC has started dosing in Phase I clinical trial of the world’s first nanocellular technology-based anti-Covid-19 vaccine in healthy adults.

Adaptimmune and Genentech partner on allogeneic cell therapies

Adaptimmune Therapeutics has signed a strategic partnership and licence agreement with Roche Group member, Genentech, for the development and commercialisation of allogeneic cell therapies across several cancer indications.